The Impact of Illicit Drug Use on Spontaneous Hepatitis C Clearance: Experience from a Large Cohort Population Study
Hossein Poustchi, Saeed Esmaili, Ashraf Mohamadkhani, Aghbibi Nikmahzar, Akram Pourshams, Sadaf G. Sepanlou, Shahin Merat, Reza Malekzadeh*
Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Tehran, Iran
Background and Aims
Acute hepatitis C infection usually ends in chronic infection, while in a minority of patients it is spontaneously cleared. The current population-based study is performed on a large cohort in Golestan province of Iran to examine the demographic correlates of Spontaneous Hepatitis C Clearance.
Serum samples used in this study had been stored in biorepository of Golestan Cohort Study. These samples were evaluated for anti hepatitis C Virus by third generation Enzyme-linked immunosorbent assay (ELISA). Subjects who tested positive were then invited and tested by Recombinant Immunoblot Assay (RIBA) and Ribonucleic Acid Polymerase Chain Reaction test (PCR). If tested positive for RIBA, subjects were recalled and the two tests were re-done after 6 months. Those subjects who again tested positive for RIBA but negative for PCR were marked as cases of spontaneous clearance.
49,338 serum samples were evaluated. The prevalence of Chronic Hepatitis C Virus (CHCV) infection based on PCR results was 0.31%. Among those who had acquired hepatitis C, the rate of SC was 38%. In multivariate analysis, illicit drug use both Injecting Use (OR = 3.271, 95% CI: 1.784–6.000, p-value<0.001) and Non-Injecting Use (OR = 1.901, 95% CI: 1.068–3.386, p-value = 0.029) were significant correlates of CHCV infection versus SC.
Illicit drug use whether intravenous or non-intravenous is the only significant correlate of CHCV, for which several underlying mechanisms can be postulated including repeated contacts with hepatitis C antigen.
Citation: Poustchi H, Esmaili S, Mohamadkhani A, Nikmahzar A, Pourshams A, et al. (2011) The Impact of Illicit Drug Use on Spontaneous Hepatitis C Clearance: Experience from a Large Cohort Population Study. PLoS ONE 6(8): e23830. doi:10.1371/journal.pone.0023830
Editor: Paul Proost, University of Leuven, Rega Institute, Belgium
Received: February 25, 2011; Accepted: July 26, 2011; Published: August 24, 2011
Copyright: © 2011 Poustchi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by Tehran University of Medical Sciences. The study was not supported by any other internal or external resources. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: firstname.lastname@example.org
Hepatitis C virus (HCV) infection is an important global health problem with estimates of 170 million HCV-infected individuals worldwide , . Prevalence of hepatitis C all around the world ranges from 0.02% to18% . In Iran, several studies have been performed on seroprevalence of HCV. Based on a comprehensive systematic review by Alavian et al. , the prevalence of HCV infection among the general population in 6 out of 30 provinces of Iran is 0.16%. Also the estimated seroprevalence of HCV in a more recent population-based study by Merat et al.  is around 0.5%, which is concordant with previous studies on blood donors (0.08%–1.3%) , .
In majority of patients exposed to HCV, the disease becomes chronic, but in a proportion of cases ranging from 14% to 45% the virus is spontaneously cleared from the body and the Ribonucleic Acid Polymerase Chain Reaction test (PCR) test becomes negative –.
Several factors have been proposed as correlates of HCV persistence, including viral and demographic factors, and also route of disease transmission. –, –.
Among demographic factors, male gender –, older age , , and ethnic background , ,  are suggested as correlates for HCV persistence. Host genetic variation is also assumed to explain the heterogeneity in HCV persistence across individuals because such differences occur even if individuals are exposed to the same HCV strain , , .
Certain high risk behaviors also increase the risk of HCV persistence, namely illicit drug use (both Injecting and non-Injecting) , , alcohol consumption , , and unprotected sexual behaviors that lead to co-infection with Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) , –. Still, there are major controversies on the role of these risk factors in various studies.
Along with effective prevention of HBV by universal vaccination in developing countries including Iran, HCV is becoming a more important public health concern replacing HBV –. There are quite a few studies that report the high rate of HCV co-infection with HBV, HIV, and venereal diseases such as syphilis in Iran ,  especially among prisoners , which needs immediate attention. Appropriate policy-making in this regard necessitates accurate estimation of HCV burden. Distinguishing patients who spontaneously clear HCV from those who develop progressive liver disease and their risk factors is crucial for decision making.
In the current study, we have determined the rate of HCV spontaneous clearance (SC) and its demographic and host correlates in a large prospective population-based study in Iran.
All subjects whose serum had tested positive for third generation Enzyme-linked immunosorbent assay (ELISA) were recruited for baseline examination and were recalled after 6 months and no subject was missed in the prospective phase of the study. Three hundred and eighty one (381) subjects tested positive for ELISA, among them, 247 subjects were also positive for Recombinant Immunoblot Assay (RIBA), therefore 134 subjects were labeled as false positive. Chronic HCV infection (CHCV) was confirmed in 152 subjects by PCR and the 95 cases with negative PCR was labeled as SC. During repeat serological testing after 6 months all CHCV subjects remained positive and in none of SC cases did the result of the test change. The HCV seroprevalence in Golestan cohort was 0.5% based on the result of RIBA, and 0.31% based on the result of PCR and 38.5% of infected subjects had spontaneously cleared the infection.
There was no significant difference in the mean age between the 4 groups (CHCV, SC, false positives, and HCV negatives). The frequency of males was significantly higher among subjects with CHCV infection (73.7%) and cases of SC (52.6%) than false positives (47.0%) and HCV negatives (40.0%) (p<0.001).
The correlates of HCV acquisition in univariate and multivariate logistic regression were sought. The ultimate correlates in multivariate analysis were: history of blood transfusion, history of imprisonment, family history of hepatitis, cigarette smoking, Non-Injecting Drug Use (Non-IDU), and Injecting Drug Use (IDU) (table 1).
To the best of our knowledge, the current study is the first that has been conducted in such a large scale on HCV spontaneous clearance in Iran. In this study we were able to demonstrate that 38.5% of HCV infected subject might clear HCV infection spontaneously which is in agreement with many previous studies –, –, . Also we found that both IDU and non-IDU are the main correlates of CHVC that significantly decrease the chance of SC among those patients who have acquired HCV infection.
Over 50% of the total estimated 170 million HCV cases in the world occur among illicit drug users and over 75% of incident infections occur in this population . It is known that, illicit drug use is the major correlate of HCV persistence , , . Several hypotheses have been suggested to explain the underlying mechanisms of this finding which mainly include: inefficient immunological response  which is due to HIV in co-infected subjects , ,  other co-infection or co-morbidities , , and finally repeated -infection .
As for IDU, frequent monitoring of HCV infection status among those who clear a primary infection demonstrated that re-infection of HCV following control of a primary infection is common , with detection of one or more subsequent infections in almost 50% of cleared subjects . In a study by Aitken and colleagues, re-infection was documented in 46% of previously cleared IDUs . This data suggests that prior clearance of HCV infection may not provide immunity against re-infection. However it is of interest to know that the rate of self limited infection in subjects who previously cleared the virus is higher than subjects who do not clear the virus after initial infection , . Furthermore, maximum viral load and also duration of viremia in re-infected cases are lower compared to the primary infection .
Our results are in discordance with findings of Lewis-Ximenez et al. , who found no relationship between illicit drug use or age and rates of SC. The only correlate of CHCV infection reported by them was low HCV antibody values . The insignificant results in this study may have been due to the small sample size. Similarly, Santantonio et al.  found no demographic factors as correlates of HCV persistence. The possible explanation is that IDUs in Italy may be less likely to reuse syringes for drug injection.
Our results on the role of Non-IDU in HCV persistence are in accord with previous studies , , , but there are no agreed upon mechanism for this finding. Some studies imply that nasal inhalation or oral exposure may be plausible routes of transmission probably through shared intranasal canola contaminated with blood .
In our study, the seroprevalence of HCV based on RIBA is 0.5%, which is similar to that reported by Merat et al. ; however, the seroprevalence of HCV in our results based on PCR is 0.31% which is again similar to that reported by Alavian et al. . The risk factors that correlate with HCV acquisition in our study (table 1) are also similar to many previous reports.
In the current study, the rate of SC is significantly higher among females versus males. Also in the univariate logistic regression, male gender is a significant predictor of HCV persistence, and this is supported by previous data , , . Some previous studies have reported that the rate of SC is higher among females. The apparently higher rate of HCV SC in females is postulated to be due to effect of sex hormone  or attributed to genetic and immunological differences between males and females. In our study, gender was not found to be a significant correlate of HCV persistence in multivariate logistic regression analysis. The main reason for this finding may be the fact that IDU is more common among males. This finding implies that the inherent attributes of female gender have probably no direct effect on the natural history of CHCV which is discordant with previous studies , , , , . With a similar justification, the seemingly protective role of body piercing in HCV persistence is due to the fact that in our study, women added up to 95.4% of subjects who had pierced while the percentage declined to 1.3% among those who had not, which shows that body piercing is associated with gender and thus is a confounder.
Since the Golestan Cohort Study (GCS) is an aged cohort and the median age of our subjects was 54 years, re-infection might have happened several times and seroconversion might have happened at unknown time; therefore, our cohort may represent a selection of subjects who have recovered from multiple bouts of HCV infections. Studies in older HCV infected subjects documented that prior clearance of HCV decreases the rate of persistent re-infection compared to initial infection , ; therefore, the duration of re-infection in subjects who have cleared multiple infections may be progressively shorter with each re-infection and this may have been the case in our study too but longer follow up is required to document this claim.
Lastly we compared the rate of SC in Turkmens versus non-Turkmens and in Turkmens versus immigrants from the southern province of Sistan and Balouchestan, who are the second major ethnic group residing in Golestan. Contrary to other studies, we did not find significant difference in the rate of SC between different ethnic groups residing in the province of Golestan. , , .
The main strengths of our study are the prospective population-based design and the large sample size which have been tested. The main limitation is the absence of young subjects in study population. Other limitation includes absence of HCV genotype data.
In conclusion this study revealed a 38.5% spontaneous clearance rate among HCV infected subjects in Golestan. We were able to demonstrate that illicit drug use, either Injecting or non-Injecting, are the main correlates of HCV persistence in Golestan province. Harm reduction interventions including distribution of sterile syringes among IDUs, can be an effective strategy to prevent HCV infection and re-infection in this population, which may play an important role in reducing the burden of HCV infection in Iran. Further studies which include younger age populations are necessary in future.
View Complete Data;
Materials and Methods
The Impact of Illicit Drug Use on Spontaneous Hepatitis C Clearance: Experience from a Large Cohort Population Study
Get Updates For HCV New Drugs Delivered By Email
Check Out The Website
Hepatitis C New Drug Research And Liver Health
RSS Feed; Website Updates
HCV In The News
DDW 2013 - May 18-21, 2013 - Orlando, FL
Digestive Disease Week - The conference will showcase the latest advances in GI research, medicine and technology in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery
Hot Topics - May 2013
If the past is a harbinger of the future, therapy for HCV infection will probably continue to advance at a brisk pace. Many additional potent agents are in the clinical pipeline, and interferon-free regimens are likely to dominate the HCV therapeutic landscape within the next 5 years.....
At this year's EASL in Amsterdam with over 9600 delegates the phase III study results for the two "second wave HCV protease inhibitors" faldaprevir and simeprevir each in combination with pegylated interferon (PEG-IFN) and ribavirin (RBV) for HCV genotype 1 patients were presented as well as the phase III findings for the polymerase inhibitor sofosbuvir again in combination with PEG-IFN/RBV for treatment of genotypes 1,4,5 and 6. In addition phase III results of the first interferon free combination of sofosbuvir with ribavirin for treatment of genotype 2 and 3 were presented....
Care for hepatitis C is evolving rapidly, with increasingly effective and better-tolerated antiviral therapies being evaluated and approved for use. It's clear, however, that not everyone who would qualify for therapy has been tested and identified, referred for appropriate care, and offered or given the best therapy available. Furthermore, currently used antiviral drugs - pegylated interferon and ribavirin "base" plus either telaprevir or boceprevir - can cost more than $70,000 for a full course of therapy. It is expected that the new oral antiviral agents will be just as expensive, at least in the short term.
Hepatitis C Therapy Update 2013-What About Interferon-free Regimens?
U.S. FDA grants priority review to Simeprevir (TMC435) for combination treatment of genotype 1 chronic hepatitis C
AbbVie's ABT-450- Breakthrough Therapy Designation from the U.S. Food and Drug Administration Granted to Investigational HCV Regimen
Gilead Sofosbuvir and ledipasvir: Plans to initiate a third Phase 3 clinical trial with and without ribavirin
Cost will limit uptake of off-label Gilead/Bristol-Myers Squibb Hep C combo, despite best-in-class data
ViewPoints: New Hep C data validates Gilead's solo approach
Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir (GS-7977) for the Treatment of Hepatitis C-- Sofosbuvir Would Form Basis of First All-Oral Regimen for HCV Genotype 2 and 3 Patients, and Interferon-Sparing Regimen for Genotype 1 Patients --
Anemia Top Side Effect of HCV Antivirals
Hepatitis C Virus Infection: Looking for Interferon Free Regimens
Review: NS5A Inhibitors in the Treatment of Hepatitis
VX-135/daclatasvir: Vertex signs agreement with Bristol-Myers for all-oral midstage studies for hepatitis C treatments
Simeprevir (TMC435) - Janssen Submits New Drug Application to U.S. FDA
Miravirsen- Hepatitis C drug goes after patients’ RNA
Update on Phase 3 Study of Oral Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients
Hepatitis C - Presidio Collaboration with Boehringer Ingelheim for interferon-free Phase IIa clinical trial
Gilead hepatitis C drug sofosbuvir (GS-7977) meets goal of fourth late-stage study
EASL-Burden of Liver Disease in Europe: Looks at leading causes of cirrhosis and primary liver cancer in Europe
Gilead Announces SVR Rates from Two Phase 3 Studies of Sofosbuvir (GS-7977) for Hepatitis C
Potential IFN-Free Regimens For HCV
IDX184 and IDX19368 - Idenix drops development of hepatitis C drugs
Interferon free regimens for the “difficult to treat”: are we there?
Current Prospects for Interferon-free Treatment of Hepatitis C in 2012
Numerous other DAAs are in clinical development, and phases 2 and 3 trials are evaluating interferon-free combination DAA therapy. Interferon-free sustained virologic responses have now been achieved with combinations of asunaprevir and daclatasvir; sofosbuvir and ribavirin; sofosbuvir and daclatasvir; faldaprevir and BI207127; ABT-450, ritonovir and ABT-333; ABT-450, ritonovir and ABT-072; miracitabine, danoprevir and ritonavir; and alisporivir and ribavirin. Some drugs are genotype-specific in their activity, whereas others are pan-genotypic, and differential responses for the genotype 1 subtypes 1a and 1b have emerged with many DAA combinations. Viral breakthrough and resistance are important considerations for future trial design. The prospect of interferon-free combination DAA therapy for hepatitis C virus is now finally becoming a reality.
2013-Guide to Clinical Trials for People with Hepatitis C
Bristol-Myers to Hold Talks On Settling Claims of Hepatitis C Patients
Treat Now or Wait?
The debate rather to treat HCV now or wait is ongoing, in the journal "Liver International" factors which affect the decision to treat now or delay therapy are discussed. You can view the article here: Patients with HCV and F1 and F2 fibrosis: treat now or wait?
Lucinda K. Porter, RN Shares A Personal Experience: Starting 12 weeks of sofosbuvir, GS-5885, and ribavirin
Coming in September 2013
A second book authored by Lucinda K. Porter, RN: Hepatitis C Treatment One Step at a Time: Inspirational Readings and Practical Tips for Successful Hepatitis C Treatment
FREE FROM HEPATITIS C
Clinical Trial Updates
ClinicalTrials.gov: updated in the last 30 days
HCV PipelineHCV Advocate - News & Pipeline Blog
Chronic Hepatitis C Infection: Treat Now or Wait?
INCIVEK® (telaprevir)-Updates label after reports of a ‘small number of fatal skin reactions’
Vertex discloses Hep C drug deaths
HCV Transplant Studies GS-7977 Also Telaprevir & Boceprevir
Perspectives and challenges of interferon-free therapy for chronic hepatitis C
Hepatitis C–What Are Your Treatment Choices: New Webinar
Setbacks in HCV Drug Development Highlight Uncertainties in Treat or Wait Decisions
So You Think You’re a Hepatitis C Expert
Back in July Clinical Care Options released part one of a three part online quiz containing 35 questions on hepatitis C, answered by nine world-renowned hepatology experts. In October CCO released part two of the series which included case scenarios from 11 leading international experts on hepatitis C, and today part three was released!
Idenix: FDA Places IDX19368 Hepatitis C Treatment on Clinical Hold
IDX184-Idenix hepatitis C drug put on partial hold
BMS halts the development of BMS-986094 due to patient death
BMS-986094-Bristol-Myers Sued Over Heart Damage In Hepatitis C Drug Trial
The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), will take place April 24 to 28 in Amsterdam, The Netherlands.
EASL Website - Press Room
EASL Abstract Search
Click here for a downloadable PDF version of the Abstract Book.
Tips For Viewing Hepatitis C Abstracts
Download now the ILC 2013 congress app and have full access to the scientific programme, posters, abstracts, floorplans and more!
EASL: Direct-acting antivirals now ready for prime time with promising alternatives on the way
AbbVie is a new, independent biopharmaceutical company composed of Abbott’s former proprietary pharmaceutical business
ABT-267, ABT-333-non- nucleoside, ABT-450/r
r = ritonavir
Faldaprevir/ (BI 201335)
MK-5172 and Daclatasvir
MK-5172 and Daclatasvir-Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II Clinical Trial
CCO's independent conference coverage
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
Long-term management of the successful adult liver transplant: 2012 practice guideline by the -AASLD
VA guidelines for management and treatment of HCV, published in the American Journal of Gastroenterology
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
Nonalcoholic Fatty Liver Disease (NAFLD)
New Clinical Practice Guideline Developed for Nonalcoholic Fatty Liver Disease
2012-New guidelines on the management of hepatocellular carcinoma (HCC).
These guidelines result from a joint collaboration between the European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of Cancer (EORTC).
EASL-April 2012 Revised Clinical Practice Guidelines on the Management of Chronic Hepatitis B
HCV Information and Educational Resources
Clinical Liver Disease -Digital Liver Disease Journal
This journal is an official digital educational resource from the American Association for the Study of Liver Diseases.
Visitors are able to view videos, full data, and download files in either HTML or PDF formats
View all issues here.
Projects In Knowledge
Offered at the site is a program series of HCV Video Case Vignettes. In the videos individual patient case studies are discussed, topics include side effects, drug-drug interactions, treatment duration, and outcome.
AASLD - Liver Learning
If you haven't yet explored the "Liver Learning" section available @ the AASLD web site you're missing out on the November meeting webcasts, video podcasts, abstracts and more.
Other HCV Sites:
These links will take you to the premier Hepatitis C sites and keep you informed with breaking news, clinical studies, new drugs, podcasts, newsletters, support, personal experiences, chat rooms, forums and more.
2012 Articles Of Interest
2012-New Antiviral Agents for Hepatitis C
This article describes the direct acting antivirals and host-targeted agents that have recently been approved or have been tested in HCV-infected patients and discusses their two current paths of clinical development: with or without interferon-α.
Standardization of Terminology of Virological Response in the Treatment of Chronic Hepatitis C
Protease inhibitors: Silver bullets for chronic hepatitis C infection?
Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), added to standard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral agents to become the new standard of care for this population.
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
A significant increase in the number of patients with CHC to be treated is expected for 2012, with triple therapy regimens that are more complex. These expected developments represent a significant challenge and will stretch current resources.
The present Swiss Association for the Study of the Liver (SASL) expert opinion statement is not intended as guideline but shall provide some guidance on the management of CHC genotype 1 and the use of TPV and BOC
If you have just been diagnosed with hepatitis C or considering HCV therapy click here for easy to understand information.
Patient Assistance Program
INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Programs
Prescribing Information for INCIVEK including the Medication Guide.
VICTRELIS™- Boceprevir: Prescribing Information and Medication Guide
Hepatitis C-New Protease Inhibitor (NS3/4A) Drug Resistance Test
LabCorp has begun offering nationwide its hepatitis C GenoSure NS3/4A assay, which is designed to identify NS3 and NS4A mutations and NS3-associated resistance to a pair of recently approved HCV protease inhibitors.
- (PPI-668) w-Faldaprevir (BI201335) and BI207127 (1)
- 2012 -168 Pages Of HCV FAQs (1)
- A 2013 Conference on Retroviruses and Opportunistic Infections (4)
- A Guide 2011-Management Of HCV (2)
- A Guide 2012-Guideline for Nonalcoholic Fatty Liver Disease (1)
- A-2012 EASL-AASLD Special Conference (2)
- A-2012 Update on the Diagnosis and Treatment of Hepatitis C (1)
- A-2012-New guidelines on the management of hepatocellular carcinoma (HCC). (1)
- A-Current status and future directions in the management of chronic hepatitis C (1)
- a-DDW 2011 Meeting (11)
- a-DDW 2012 meeting (21)
- a-DDW 2013 meeting (16)
- A-EASL 2011 Summary (1)
- A-EASL 2012 (79)
- A-EASL 2012 - Guidelines on the Management of Chronic Hepatitis B (1)
- A-EASL 2012 Index (1)
- A-EASL 2012 Internet Symposium (2)
- A-EASL 2012 Summary Of The Meeting (1)
- a-EASL 2013 (50)
- A-EASL 2013 Summary Of The Meeting (1)
- a-EASL 2013-abstract search (1)
- A-New targets for antiviral therapy (82)
- A-Patients who will remain untreated in the era of triple therapy (1)
- AASLD 2011 updated hepatitis C practice guidelines (2)
- AASLD 2012-63rd Annual Meeting (73)
- AASLD 2012-STC (1)
- AASLD Nov 2011 (60)
- AASLD Nov 2011-Pocasts-Videos-Webcasts (2)
- AASLD Nov 2011-Summary (1)
- AASLD Oct2010 (80)
- AASLD Oct2010-summary (1)
- ABT-267 (9)
- ABT-333-non- nucleoside (10)
- ABT-450 (9)
- ABT-450/r (19)
- ABT-450/r and ABT-072 (4)
- ABT-450/r plus ABT-333 (8)
- Acai Berry Scam (1)
- acetaminophen (2)
- ACH-1625 (15)
- ACH-2684 (5)
- ACH-2928 (2)
- ACH-3102 (9)
- ACLF (1)
- acupuncture (2)
- acute HCV (4)
- acute HCV-when to begin therapy (1)
- acute liver failure (1)
- addiction (14)
- Adherence to therapy (12)
- ADI-PEG 20 (1)
- AIDS (2)
- alcohol consumption (12)
- alisporivir (4)
- alpha-fetoprotein (1)
- ALS-2200 (3)
- ALS-2200 (VX-135) (11)
- ALS-2200 and ALS-2158 (3)
- ALS2158 (1)
- amazing sunday (1)
- ANA598 (5)
- ANA598-setrobuvir (2)
- ANA773 (1)
- ANA958 (1)
- anemia (7)
- antidepressants (4)
- antioxidants (1)
- arthritis (4)
- ascites (9)
- asthma (1)
- Asunaprevir (1)
- autoimmune hepatitis (1)
- Avila Therapeutics™ (1)
- AVL-192 (2)
- bath salts-spice (12)
- Bavituximab (5)
- BCX5191 (2)
- BCX5191-withdrawn (1)
- Behind the Headlines (8)
- Behind the Headlines-Vaccine (1)
- Best Hospitals (5)
- BI 201335 and BI 207127 (10)
- BI 207127 (7)
- BILB 1941 (1)
- Bioartificial Liver (3)
- biological "devices" to program cells (1)
- Biopump (1)
- BioScience (2)
- biosimilars (6)
- BIT225 (2)
- BL-8020 (2)
- blood safety (2)
- blood scandal (3)
- bms-650032 (6)
- BMS-650032 (Asunaprevir) BMS-790052 (Daclatasvir) (10)
- BMS-650032 and BMS-790052 (5)
- bms-790052 (18)
- bms-790052-declatasvir (10)
- BMS-986094-INX 189 halted (8)
- BMS-986094-INX 189 on hold (7)
- boceprevir (98)
- Boceprevir FDA Transcript (1)
- boceprevir patient guide (1)
- boceprevir-drug assistance program (3)
- boceprevir-Medication Guide-Prescribing Info (1)
- boceprevir-victrelis (178)
- boceprevir-victrelis-Cost (1)
- boceprevir-victrelis-mericitabine w-SOC (1)
- Bowel (1)
- Brain (7)
- Caleco Pharma (1)
- Canada (2)
- cancer (14)
- cancerous growths gallbladder and/or the bile duct (1)
- CDC (4)
- CDC- World Hepatitis Day 2011 (1)
- CDC- World Hepatitis Day 2012 (4)
- Chat room (3)
- children treating HCV (15)
- chronic disease (2)
- chronic fatigue (16)
- chronic hepatitis c (2)
- chronic liver failure (2)
- chronic pain (3)
- cirrhosis (173)
- cirrhosis-complications (10)
- cirrhosis-Vibrio vulnificus-raw oysters (1)
- clinical trials (120)
- clinical trials-Pro-Con (4)
- coffee (21)
- Colloidal silver (1)
- colonoscopy (2)
- comorbidities HCV anti-viral treatment and disease (1)
- compensated cirrhosis (11)
- Complementary and Alternative Medicine (17)
- Counterfeit drugs (7)
- covalent inhibitor (2)
- Creating Functional Hepatic Tissue (1)
- Cryoglobulinemia (5)
- CTS-1027 (5)
- Cyclophilin Inhibitors (1)
- Daclatasvir (3)
- daclatasvir-peg/riba (3)
- Daclatasvir/Asunaprevir (3)
- daclatasvir/asunaprevir/BMS-791325 (5)
- Daily Consensus Interferon (1)
- Danoprevir (12)
- Danoprevir/Mericitabine (2)
- DEB025 (2)
- DEB025- alisporivir (4)
- decompensated cirrhosis (18)
- Dental (3)
- Depression (16)
- diabetes (100)
- diabetes-insulin resistance (8)
- Digestion (2)
- Direct-acting Antivirals (11)
- disease progression (11)
- donation (13)
- drug alerts (1)
- Drug Assistance Programs (5)
- Drug Resistance Test (1)
- drug shortages (1)
- dry eye (3)
- dyspepsia (1)
- EASL (59)
- Economic Burden HCV (2)
- ELAD® Bioartificial Liver (1)
- encephalopathy (28)
- endoscopy (1)
- Epidemic HCV (9)
- Epogen (4)
- ESLD (1)
- faldaprevir (7)
- faldaprevir/ (BI 201335) (24)
- faldaprevir/BI 207127 (1)
- fatigue (7)
- Fatigue-Cognitive Function-Sleep Quality (2)
- Fatty Liver (113)
- Fatty Liver-RP103 (1)
- FDA (68)
- fibromyalgia (7)
- Fluvastatin (2)
- Foodborne illness (15)
- G7128 (1)
- gallbladder (1)
- gallstones (9)
- gastritis (1)
- Gastroenterologist (1)
- geno 2 (16)
- geno1 (92)
- geno2 (32)
- geno3 (53)
- geno4 (28)
- geno5 (5)
- geno6 (10)
- genotypes;All (14)
- green tea (2)
- GS-5885 (4)
- GS-7977 now Sofosbuvir (65)
- GS-7977 now Sofosbuvir and simeprevir (TMC435) (6)
- GS-7977 now sofosbuvir / GS-5885 now ledipasvir (14)
- GS-7977 now Sofosbuvir Plus Riba (2)
- GS-7977 now Sofosbuvir/BMS-790052 now Daclatasvir (10)
- GS-7977 Plus Peg/Riba (3)
- GS-9190 (7)
- GS-9256 (6)
- GS-9451 (2)
- GSK2336805 (3)
- Gut Bacteria (1)
- H pylori (1)
- HALL OF SHAME (42)
- HALT-C (8)
- hav (6)
- hav vaccine (1)
- hbv (96)
- hbv vaccine (1)
- HCV Australia (6)
- hcv abstracts (231)
- HCV Awareness (69)
- HCV Awareness-screening strategies (19)
- HCV Baby Boomers (31)
- HCV cardiovascular disease (1)
- HCV diet (3)
- HCV Forum (1)
- HCV hypertension (1)
- HCV natural compounds (1)
- HCV neurocognitive function (1)
- HCV News (1276)
- HCV News-weekly rewind (20)
- HCV pregnancy (6)
- HCV Protease Inhibitors in Active Drug Users (1)
- HCV replication (3)
- HCV research (93)
- HCV Self-management (1)
- HCV symptoms (3)
- HCV tests (19)
- HCV tests-endoscope (1)
- HCV transmission FAQ (1)
- HCV Vaccine (24)
- HCV vaccine GI-5005 (7)
- HCV Vaccine-TG4040 (MVA-HCV) (2)
- HCV Worldwide (29)
- HCV Worldwide Asia Australia Egypt (2)
- HCV Worldwide-Europe Canada Israel (1)
- HCV Your Health (3)
- HCV-autoimmune diseases (1)
- HCV-Breast Cancer Risk (1)
- HCV-Editorial (12)
- HCV-Education (56)
- HCV-elderly (3)
- HCV-Insulin resistance (11)
- HCV-Statins (7)
- HCV/HBV/HIV special populations (1)
- Health Reform (3)
- Health Reform-Insurance (4)
- Healthy you (28)
- hemochromatosis (1)
- HepaFat™ (1)
- Hepatitis-related Renal Disease (1)
- hepatocyte cell transplantation (1)
- hepatologist (1)
- hepatoSys Virtual Liver Network (1)
- herb (31)
- herb-kava (2)
- HEV (3)
- History of HCV (3)
- HIV (114)
- HIV-children (3)
- hiv/hbv-coinfection (1)
- HIV/HCV (70)
- hot topic (9)
- HTAs-host-targeting agents (1)
- human genome (6)
- human interferon alpha lozenges (2)
- Idenix Reports Positive Interim Data for Hepatitis C Drug (1)
- IDX184 (21)
- IDX184-Discontinued (1)
- IDX19368-Discontinued (1)
- IDX19368-hold (2)
- IDX719 (9)
- if I had.. (9)
- IFNL 4 (1)
- IL-7(CYT 107) (1)
- IL28B (62)
- IL28B Test (2)
- immune system (9)
- IMO-2125 (6)
- Inflammation (3)
- Inflammation Liver (1)
- Inflammatory Bowel Disease (1)
- INFRADURE Biopump (1)
- Inspirational (25)
- Insurance (1)
- Insurance medicare (1)
- interferon (5)
- Interferon Free Combinations (111)
- Interferon lambdas (1)
- interferon-free therapies (2)
- Investment News HCV Drugs (22)
- INX 189 (13)
- IP-10 (1)
- ITX-5061 (1)
- Joint pain (1)
- Just for fun (5)
- JX594/TG6006 (2)
- Lambda (7)
- ledipasvir (GS-5885) (4)
- Lichen Planus (5)
- List Peer-Reviewed Journals (2)
- Liver Abscess (2)
- liver biopsy (13)
- liver biopsy-necessary in all genotypes? (1)
- liver cancer (228)
- Liver cancer CF102 (2)
- Liver Cancer Treatment (73)
- liver cancer treatment-radiofrequency ablation (RFA) (2)
- Liver Cancer-HEAT Study of ThermoDox(R) (3)
- liver cancer-MCT-465 and MCT-485 (1)
- liver cancer/sorafenib (4)
- Liver Cysts (1)
- liver disease (15)
- Liver Fibrosis (96)
- liver function tests (12)
- liver health (66)
- Liver Injury Dietary Supplements (2)
- Liver Injury-Shark liver oil (1)
- Liver Pain (6)
- liver surgery (2)
- liver/anatomy (1)
- locteron (1)
- Locteron/interferon (2)
- lymphoma (3)
- M11-602 (1)
- marijuana (27)
- marijuana-based prescription drug (1)
- MBX-700 and MBX-701 (formerly SCH 900942 and SCH 900188) (1)
- Mediterranean diet (1)
- Men and HCV (4)
- microspheres (3)
- Milk thistle (22)
- Miracle Mineral Solution-MMS (1)
- Miravirsen (7)
- miRNAs (1)
- MK-5172 (11)
- MK-5172/peg/riba (1)
- MK-5172/Vaniprevir(MK-7009) (1)
- MK-7009 (4)
- monoclonal antibody GS-6624 (1)
- Morbidity-SVR (3)
- Mortality (12)
- myocardial infarction (1)
- myocarditis (1)
- nanoparticles (3)
- Nanotechnology (3)
- Natural leukocyte interferon alpha (Alfaferone) (1)
- Neutropenia HCV Treatment (4)
- new drugs (3)
- new hcv drugs (55)
- newly diagnosed (8)
- newsletters (45)
- Nitazoxanide (2)
- noninvasive tests for fibrosis (36)
- nonresponders (7)
- NS5A inhibitor (2)
- NSAID (7)
- nucleoside inhibitors (1)
- null responders (10)
- occult hepatitis C virus infection (1)
- Off Topic (31)
- online pharmacy (1)
- Oral interferon (1)
- organ harvesting (11)
- organ trafficking (5)
- organ trafficking- U.S (1)
- organ-imported tainted tissue (1)
- Origin Of Hepatitis (1)
- Other Conditions Related To HCV (46)
- Other Conditions Related To HCV-Vasculitis (5)
- Other Health News (91)
- OTHER INFECTIOUS DISEASE (20)
- outsourcing clinical trials (3)
- outsourcing drugs (7)
- partial responders (3)
- Pediatric liver disease (1)
- Pegasys (10)
- Peginterferon (74)
- PegIntron (4)
- Peripheral Neuropathy (2)
- PF-05095808 (1)
- Pharmaceuticals (135)
- Pink eye-Sty-and other eye conditions (1)
- platelets (3)
- polymerase inhibitor (16)
- Porphyria Cutanea Tarda (PCT) (2)
- Post Treatment Symptoms (1)
- PPI-383 (1)
- PPI-461 (3)
- PPI-668 (3)
- primary biliary cirrhosis (PBS) (1)
- probiotics (1)
- procrit (4)
- prognostic test:response to therapy (1)
- promacta (1)
- prostate cancer (1)
- protease inhibitor (33)
- protease inhibitor- (NS3/4A) Drug Resistance Test (2)
- PSI-7977 (24)
- PSI-7977 and PSI-938 (1)
- PSI-7977-TMC435 (3)
- PSI-7977/ Daclatasvir-(BMS-790052) (1)
- PSI-938 (6)
- PSI-938-Halted (1)
- Pulmonary fibrosis (1)
- Quackery (10)
- Questions About HCV (4)
- rash (10)
- recall (25)
- regeneration (5)
- regenerative Medicine (15)
- relapse (8)
- resistance to protease inhibitors (16)
- response-guided therapy (4)
- RG7128 (9)
- ribavirin (25)
- Ritonavir (1)
- rituximab (2)
- salt (4)
- SB 9200 (1)
- scientists grow human livers in laboratory (7)
- SCY-635 (5)
- SCY-641 (1)
- Seasonal Flu Vaccine (9)
- selenium (2)
- setrobuvir (1)
- side effects (65)
- side effects-direct-acting antivirals (18)
- side effects-eyes (7)
- side effects-telaprevir (3)
- silibinin (4)
- silymarin (4)
- Simeprevir (11)
- SIR-Spheres microspheres (2)
- Small fiber neuropathy (2)
- Sorafenib (6)
- sovaprevir (3)
- Sovaprevir (Formerly ACH-1625) (5)
- Sovaprevir/ACH-3102 (2)
- sphincter of Oddi (3)
- spleen (6)
- SPONTANEOUS CLEARANCE (12)
- Standardization of Terminology of Virological Response (1)
- Starting HCV Treatment (69)
- STAT-C (3)
- stem cell lawsuit (2)
- stem cell tourism (7)
- stem cell-diabetes (1)
- stem cells (76)
- stem cells-pluripotent (2)
- stem-cell-derived liver tissue model (1)
- supplements (13)
- support (45)
- support-hotline (5)
- Surgery in liver disease (2)
- svr (68)
- SVR-Mortality (4)
- svr-pitavastatin (Livalo) (1)
- svr-rapid response (1)
- SVR24-SVR12-SVR4 (8)
- Tattoos (2)
- telaprevir (125)
- Telaprevir FDA Transcript (1)
- telaprevir medication guide (1)
- telaprevir patient assistance (3)
- telaprevir prescribing information (1)
- telaprevir with VX-222 (20)
- telaprevir-incivek (205)
- telaprevir-incivek-Cost (3)
- Tenofovir (2)
- Terry's nails (1)
- TG4040 (2)
- Thalidomide (1)
- The natural history of hepatitis C (2)
- Therapy-over the age of 65 (1)
- TheraSphere (1)
- Thrombocytopenia (4)
- Thrombocytopenia-Promacta (1)
- thrombosis (3)
- thyroid (11)
- Timeline Hepatiits (1)
- TMC278 for HIV (1)
- TMC435 (26)
- TMC435 (Simeprevir) (27)
- TMC435-BMS-790052 (3)
- TMC647055 (3)
- TMC647055 and IDX719 (1)
- TMC649128 (4)
- toxicity (25)
- transmission (64)
- Transmission clinical setting (84)
- Transmission clinical setting-Government Report 2012 (1)
- Transmission of HCV Through Transplanted Organs (2)
- transmission-needlestick (2)
- transplant (162)
- transplant tourism (7)
- Transplant- Telaprevir/Boceprevir (3)
- transplant-certican (1)
- Transplant-GS-7977 now Sofosbuvir (1)
- transplant-HCV recurrence (2)
- transplant-IL28B (1)
- transplant-MELD (6)
- Triad Prep Pads (16)
- TT-034 (1)
- tylenol (11)
- upper abdominal pain (2)
- varices (14)
- video (259)
- video viral load test(PCR) (1)
- viral load (9)
- Virtual Liver (1)
- virus research (2)
- vitamin A (6)
- vitamin B12 (3)
- vitamin D (34)
- vitamin E (6)
- Vitamin E-TE/TCP supplements (1)
- vitamin k (1)
- vitamins (7)
- warning-black cohosh (1)
- weekend reading (42)
- wellness (52)
- what is hepatitis c (1)
- women (8)
- Xifaxan (1)
- XIX International AIDS Conference (4)
- zalbin (1)
- zinc (1)
- ► 2013 (437)
- ► 2012 (1293)
- Early TIPS for Ascites Study Seeks to Improve Surv...
- IL28B SNPs and haplotypes for prediction of drug r...
- Aug 31 Hepatitis New Ticker;Telaprevir Markedly Im...
- Hepatitis C-TMC435 ;MedivirAB Completed Enrollment...
- FDA Request That H&P Recall Povidone Iodine Prep S...
- Mythbusters: Learn the Truth about Food Safety in ...
- Facebook App; Watching Viruses "Friend" a Network
- Hepatitis C; Response To Treatment Geno 3-fibrosis...
- Hepatitis; FDA Draft Guidance Document May Limit P...
- Video; Victrelis, and Incivek-2 new drugs to fight...
- Hepatitis C-Needlestick Injuries – A Nurse's Story...
- Hepatitis C Monday News Ticker; Paediatric HCV, Tw...
- Canada-Victrelis;New Hep C drug priced out of reac...
- Fatigue In HCV Infection: A Review (1989-2011)
- Differences in the Disposition of Silymarin Betwee...
- HCV News; Higher serum testosterone is assoc w-inc...
- Maternal hepatitis B and hepatitis C carrier statu...
- Telaprevir (Incivek) / Boceprevir (Victrelis)- Adu...
- HCV Resistance Testing - Launch of HCV GenoSure
- Illicit Drug Use on Spontaneous Hepatitis C Cleara...
- Hepatitis News Ticker;Launch of HCV GenoSure and I...
- Acute Hepatitis ;Following Excessive Ingestion of ...
- Hepatitis C Medical Advances; In Depth Doctor's In...
- PSI-938 Receives Fast Track from the FDA for Hepat...
- FDA Pediatric indication;Pegasys and Copegus
- Dual Hepatitis B, C Infection Ups Lifetime HCC Ris...
- Hepatitis C;Therapeutic vaccine TG4040 (MVA-HCV)-T...
- Blacks With HCV May Benefit Most From Boceprevir a...
- Multiple Ascending Dose Study of Miravirsen in Tre...
- Hepatitis C in HIV-infected Patients With Compensa...
- The ignored virus that causes liver cancer
- Saffron shows promise in preventing liver cancer
- Radioembolization improves chance of survival for ...
- Type 2 diabetes and prediabetes; Joslin researcher...
- Needle-Free, Wireless, Continuous Glucose Monitori...
- Hepatitis C Co-Pay Relief Program-Includes Medicar...
- Aug-22/Health Canada Okays INCIVEK For People With...
- Hepatitis Ticker; Monday Morning Updates
- Hepatitis Digest;Patients with cirrhosis present d...
- Hepatitis C ; liver function tests
- Hepatitis C clinical trial Opportunities In Housto...
- NASH: Fomenting fat and forecasting fibrosis
- Insulin resistance and sustained virological respo...
- Serum Biomarkers in Predicting Fibrosis Progressio...
- New Rapid HIV, HCV Tests May Improve Point-of-Care...
- Patient video;New hepatitis C Drugs and Resistance...
- "Telaprevir Alone or W-Peg/Riba Reduces HCV RNA in...
- Hepatitis C;Drugmakers knew vials led to contamina...
- Medication Errors Also Know Your Medicine’s Brand ...
- 'Bath Salts' Have Effects Similar to Meth, Ecstasy...
- Hepatitis C; Strengthening fragile immune memories...
- Hepatitis C- Thyroid dysfunction
- Hepatitis News Ticker 8-17; Guide to Clinical Tria...
- Murdoch researchers attempt to thwart hep C virus
- Use of New HCV Protease Inhibitors ‘Not That Simpl...
- Incivek/Victrelis; New approvals may change treatm...
- Cancer; Controversies in Phase I Clinical Trials
- Hepatitis Digest;HCV abstract-BMS-790052, Liver Ca...
- Hepatitis C Drug Albuferon;Doctor pleads guilty in...
- Selection of hepatitis C virus resistant to ribavi...
- Dr.MLShiffman;Complexities of Treating Chronic Hep...
- What Factors Determine the Severity of Hepatitis A...
- National Beef recalls 60,424 lbs ground beef for e...
- Camp for girls at risk of HIV aims to boost self e...
- How Fatty Diets Cause Diabetes
- Reducing pain-Sphincter of Oddi Sphincterotomy
- Medical marijuana; 50 in Yuma County apply for sta...
- Podcast; New Treatments for Hepatitis C
- Hepatitis News; Weekend Update
- Realize the advance in Hepatitis C treatment, but ...
- FYI-Which New Hepatitis C Drug do MDs Prefer? Inci...
- Hepatitis c-Insurers raising co-pays for expensive...
- Resistance exercise reduces liver fat and its medi...
- Analyst touts Pharmasset- PSI-7977
- Emmet Keeffe, Hepatitis Expert, Dead at 69
- Chromatin remodelling gene ARID2 is mutated in hep...
- 'Superdrug' Against Range of Viruses Shows Promise...
- Poor, Heterosexual Black Men: Highest HIV Risk
- AASLD:New Online Journal-The inaugural edition wil...
- Does the information provided with herbal products...
- FDA approves Gilead's once-daily HIV pill
- Hepatitis News Digest For Aug-11 2011
- 2011Chronic Hepatitis C-Full Text
- Chronic hepatitis C infection and insulin resistan...
- Action needed on Hepatitis C 'epidemic' -
- UK-Victrelis-Boceprevir HCV Drug Launched
- Hepatitis; Staging Liver Fibrosis: Liver Biopsy, I...
- DOJ Subpoena May Rattle Old Skeletons in Merck’s C...
- Impact of ribavirin on HCV replicon RNA decline du...
- Cholesterol Confusions-Does cholesterol in your fo...
- CCO--Direct-Acting Antivirals in Treatment-Naive H...
- Ottawa-HIV cases up sharply
- New Non-Invasive Technology Shows Promise in Shrin...
- Hepatocellular Carcinoma After Diagnosis of Hepati...
- Hepatitis News;Low Vitamin D Levels Could Cause Li...
- Hepatitis C-New Protease Inhibitor (NS3/4A) Drug R...
- Interferon lambdas: the next cytokine storm
- Turkey recall raises U.S. food safety questions
- Epogen-Inappropriate use of blood cell booster wid...
- USC scientist develops virus that targets HIV
- Hepatitis C virus influences neurocognitive functi...
- Merck Gets Subpoena Related to Drug MRKT-Hepatitis...
- Pakistani Region Tackling Hepatitis C With Free Tr...
- Vitamin D and Liver Disease
- Hepatitis C Clinical Trial Updates For Aug 7th 201...
- Escherichia coli, detected in 94% of retail chicke...
- Stanford legal expert discusses future of stem cel...
- Midodrine Controls Ascites, Improves Survival in C...
- Boceprevir-Victrelis-New hepatitis C drug exciting...
- Higher Muscle Mass Tied to Lower Pre-, Overt Diabe...
- Extended Interferon-Alpha Therapy Accelerates Telo...
- Watch; RF ablation alternative to surgery in early...
- Going Viral: New Hepatitis C Drugs Owe Their Succe...
- Organ Harvesting-China to crack down on illegal tr...
- Retinopathy associated with pegylated interferon a...
- Hepatitis C-Central hypothyroidism and relation wi...
- Temporal changes in HCV genotype distribution in t...
- Liver transplantation for NASH on the rise in the ...
- Thrombosis-The 50-year quest to replace warfarin
- Shock figures reveal 1,600 suffer from Hepatitis C...
- Hepatitis C Treatment;Boceprevir "Victrelis" from ...
- Hepatitis News Digest;Caffeine and alcohol consump...
- Boceprevir-victrelis-Which pegylated interferon ?
- The Role of Inflammation In Causing GI Cancers
- Diabetes Linked to Several GI Cancers
- Trial related to hepatitis C outbreak begins in Di...
- New approach a step forward for hepatitis C vaccin...
- Health Canada Clears Victrelis-Boceprevir New Hepa...
- MSD launches hepatitis C drug Victrelis in UK
- CDC: 1 death, 76 illnesses linked to ground turkey...
- Hepatitis News Ticker Updates For Aug 2
- Boceprevir response and resistance differs accordi...
- Hepatitis C study seeks more volunteers
- No Diabetes Risk Seen With Menopause
- Cyclosporine A or Tacrolimus for Hepatitis C Recur...
- Merck: Don't declare a hep C victor yet
- Patients @Rose Cancer Center may have been exposed...
- Hepatitis Aug Newsletter;HCV Advocate
- Type 2 diabetes: 'Intensive' versus 'conventional'...
- New drug regulator asks Congress for more power;ou...
- Peginterferon Maintenance Therapy in Patients with...
- First field trial for the “lab on a chip” successf...
- ▼ August 2011 (142)
Click here to order a FREE Home Access Hepatitis C Test Kit
How Soon Should I Get Tested After Exposure ?
After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure.;
FAIR USE NOTICE:
If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas. It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes. The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice
- New HCV Drugs
- Keeping current on the potential arrival of new improved hepatitis C drugs. As once a hepatitis C patient myself (I successfully treated the virus with standard HCV therapy in 2000) I understand the difficult decisions and overwhelming fear that ensues after being diagnosed with this serious and life-changing disease. This blog serves as a starting point for information on the rapidly evolving number of new agents in development to treat hepatitis C. Tina